21 June 2024
21 June 2024
The company’s two lead cancer assets include a phosphoinositide 3-kinase delta modulator, roginolisib, and cambritaxestat, an autotaxin inhibitor.
Keeping high-qualified, experienced clinical trial staff on board plays a crucial role in bringing new drugs to market. Dana Durkan of KPS Life discusses how to avoid fraudulent staff, navigate work from home dynamics, and keep hold of your most valued employees.
AstraZeneca's partner, Astex Therapeutics, stands to receive milestone payments upon the first commercial sale in the bloc.
Following recommendations made by the Commission on Human Medicines, the UK MHRA has introduced new safety measures.
Basilea sold and transferred the rights for its glioblastoma drug lisavanbulin, which has been studied in a Phase I/II study.
Based on the updated guidelines, over 50% of individuals with chronic hepatitis B infections may require treatment.
Tremfya is a fully-human monoclonal antibody and targets IL-23, a cytokine known to be a driver of immune-mediated diseases.
Biovac will deliver the IPV doses to UNICEF for distribution in GAVI-supported countries.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
